TrialCancer research and treatment2020

Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study).

Kihwan Hwang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.